Chiltern says strategic deals are good for the CRO sector
Chiltern says that strategic partnering in the contract research sector enables CROs to plan for the longer term and is having a tangible impact on brining drugs to market.
Outsourcing-pharma.com spoke with Aize Smink, Chiltern’s senior executive VP, global clinical development, who said that the drug industry’s need for efficiency is driving the formation of such deals.
He explained that these types of collaboration are not limited to Big Pharma, citing the UK-headquartered CROs agreement with a number of mid-sized drug makers as evidence.
“[Strategic partnering] allows us to focus on the long term and look at process improvement in a collaborative way with our pharma partners. So it also drives progress for CROs in that sense.”
